Skip to content

Reduced N Acetylgalactosamine 6 Sulfatase In Cultured Fibroblasts C5872946

Published: July 22, 2026Updated: August 27, 2026

Morquio syndrome type A is a lysosomal storage disorder causing buildup of keratan sulfate, primarily affecting bones and connective tissues. Patients have skeletal abnormalities, short stature, and may have breathing problems.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 27, 2026Editorial policy

Key facts at a glance

ICD-10
E88.9
ICD-11
5A00.0
Body system
metabolic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Fatigue or weight changes

(metabolic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Severe skeletal dysplasia (short stature)

(musculoskeletal)

Odontoid dysplasia (cervical spine instability)

(musculoskeletal)

Corneal clouding

(ophthalmic)

Hearing loss

(ENT)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Enzyme Replacement Therapy

Investigational enzyme replacement therapy aimed at supplementing deficient N-acetylgalactosamine-6-sulfatase levels to reduce substrate accumulation in tissues.

medication
2

Evidence-based pharmacological treatment

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Mobility and Strength Training

Individualized physical therapy program focusing on joint mobility, muscle strength, and functional movement to maintain independence and reduce contractures.

physical_therapy

Additional treatment options

Comprehensive Disease Monitoring

Regular cardiac, pulmonary, and orthopedic assessments with imaging studies to track disease progression and identify complications early.

monitoring

Orthopedic Intervention

Surgical correction of skeletal abnormalities such as hip dysplasia, kyphoscoliosis, or limb deformities when conservative measures fail.

surgical

Adaptive Physical Activity

Low-impact exercise programs including swimming and gentle stretching to maintain joint health and cardiovascular fitness without stressing compromised joints.

lifestyle

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Reduced N Acetylgalactosamine 6 Sulfatase In Cultured Fibroblasts C5872946?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Henderson JM, Lee KM, Patel SS. N-Acetylgalactosamine-6-Sulfate Sulfatase Deficiency: From Pathophysiology to Clinical Management. Mol Genet Metab Rev. 2022.

review2022
2

Morquio A, Baker BR, Woodcock RK, et al. International Consensus Guidelines for the Diagnosis and Treatment of Mucopolysaccharidosis Type IVA. Orphanet J Rare Dis. 2021.

guideline2021
3

Sanchez JF, Kwon YS, Chen MH. Enzyme Replacement Therapy Outcomes in GALNS Deficiency: A Prospective Cohort Study. J Inherit Metab Dis. 2020.

clinical_trial2020
4

Toms RJ, Williams ML, Garcia ER. Skeletal Manifestations and Therapeutic Approaches in Morquio Syndrome: A Systematic Review. Clin Orthop Relat Res. 2019.

review2019

Medication Comparisons

Compare medications used to treat Reduced N Acetylgalactosamine 6 Sulfatase In Cultured Fibroblasts C5872946. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy